Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

July 28, 2016

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
Breast Neoplasms
Interventions
DRUG

Fulvestrant

Fulvestrant IM injection.

DRUG

Sapanisertib

Sapanisertib capsule.

Trial Locations (53)

8724

New Jersey Hematology & Oncology Associates, Brick

10003

Hospital San Pedro de Alcantara, Cáceres

10549

Northern Westchester Hospital Cancer Treatment & Wellness Center, Mount Kisco

15006

Complejo Hospitalario Universitario A Coruna, A Coruña

15009

Centro Oncologico de Galicia, A Coruña

20014

Onkologikoa, Donostia / San Sebastian

20176

Virginia Cancer Specialist PC, Leesburg

25198

Hospital Universitari Arnau de Vilanova de Lleida, Lleida

26505

West Virginia University School of Medicine, Morgantown

28009

Hospital General Universitario Gregorio Maranon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

28040

Hospital Clinico San Carlos, Madrid

28220

Hospital Universitario Puerta del Hierro, Majadahonda

30008

Hospital General Universitario Morales Messeguer, Murcia

30120

Hospital Clinico Universitario Virgen de la Arrixaca, Murcia

31008

Clinica Universidad de Navarra, Pamplona

33021

Memorial Healthcare System, Hollywood

33308

Holy Cross Hospital- Bienes Cancer Center, Fort Lauderdale

33806

Orlando Health Inc., Orlando

36608

Southern Cancer Center, PC, Mobile

41009

Hospital Universitario Virgen de la Macarena, Seville

43204

Hospital Universitario Sant Joan de Reus, Reus

46009

Fundacion Instituto Valenciano de Oncologia, Valencia

46010

Hospital Clinico Universitario de Valencia, Valencia

46804

Ft. Wayne Medical Oncology and Hematology, Inc, Fort Wayne

50009

Hospital Universitario Miguel Servet, Zaragoza

55426

Health Partners Institute Park Nicollet Frauenshuh Cancer Center, Saint Louis Park

75231

Texas Oncology - Presbyterian Hospital, Dallas

75246

Texas Oncology, P.A., Dallas

75702

Texas Oncology,PA. Tyler TX, 75702, Tyler

78217

Cancer Care Centers of South Texas, San Antonio

78503

Texas Oncology- South Second Street, McAllen

78745

Texas Oncology, P.A., Austin

80045

University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP), Aurora

80228

Rocky mountain cancer centers LLP, Lakewood

81501

St. Mary'S Hospital Regional Cancer Center, Grand Junction

89074

Comprehensive Cancer Centers of Nevada, Henderson

90277

Torrance Health Association, Redondo Beach

92037

UCSD Moores Cancer Center, La Jolla

92056

North County Oncology, Oceanside

92835

St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton

93105

Cancer Center of Santa Barbara With Sansum Clinic, Santa Barbara

93309

CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA, Bakersfield

93401

PHC-SLO Oncology and Hematology, San Luis Obispo

97239

Oregon Health and Science University, Portland

90095-7077

UCLA Hematology/Oncology David Geffen School of Medicine, Los Angeles

04074

New England Cancer Specialists, Scarborough

07120

Hospital Universitari Son Espases, Palma de Mallorca

07198

Hospital Son Llatzer, Palma de Mallorca

08827

Consorci Sanitari de Terrassa, Terrassa

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic i Provincial, Barcelona

08041

Hospital De la Santa Creu i Sant Pau, Barcelona

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY

NCT02756364 - Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | Biotech Hunter | Biotech Hunter